ZBIO
$23.48
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Recent News
Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares
Zenas BioPharma secured a $250 million non-dilutive loan agreement to support commercialization and development of obexelimab. The financing follows positive Phase 3 clinical results and precedes planned marketing applications in the U.S. and Europe. Upcoming Phase 2 data for additional indications are expected to guide further development of the company’s pipeline. Zenas BioPharma, listed as NasdaqGS:ZBIO, is drawing attention with this large non-dilutive funding package alongside a...
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory
We came across a bullish thesis on Zenas BioPharma, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ZBIO. Zenas BioPharma, Inc.’s share was trading at $27.02 as of February 19th. ZBIO’s trailing P/E was 1.93 according to Yahoo Finance. Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. ZBIO is transitioning from a pre-revenue stage to […]
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets navigated a quarter supported by optimism about potential monetary easing and caution regarding economic growth and valuations. Early gains were driven by strong AI-related earnings […]
Why Zenas BioPharma (ZBIO) Is Up 24.6% After Obexelimab’s Phase 2 MS Trial Success - And What's Next
Zenas BioPharma recently reported that its lead candidate obexelimab met the primary endpoint in the Phase 2 MoonStone trial in relapsing multiple sclerosis, with a highly statistically significant reduction in new gadolinium-enhancing T1 lesions and a safety profile consistent with prior studies. The data, presented as a late-breaking oral session at the ACTRIMS Forum 2026 and supported by 24-week durability results, highlight obexelimab’s potential to curb inflammatory brain activity while...
Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit
Zenas BioPharma (NASDAQ:ZBIO) Chief Executive Officer Lonnie Moulder outlined recent clinical progress and upcoming milestones for the company’s pipeline during a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026, with much of the discussion centered on obexelimab in IgG4-related